The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,705.00
Bid: 1,704.50
Ask: 1,705.50
Change: 32.00 (1.91%)
Spread: 1.00 (0.059%)
Open: 1,685.50
High: 1,706.50
Low: 1,673.00
Prev. Close: 1,673.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

30 Dec 2020 11:52

RNS Number : 1623K
GlaxoSmithKline PLC
30 December 2020
 

GlaxoSmithKline plc (the 'Company')

Transaction notification

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr V Banga

b)

Position/status

Senior Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

 

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£13.7554

36,600

 

 

 

 

 

d)

Aggregated information

 

N/A (single transaction)

Aggregated volume Price

 

e)

Date of the transaction

2020-12-30

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFBLFXBLLEFBF
Date   Source Headline
21st Sep 202211:22 amRNSDirector/PDMR Shareholding
13th Sep 20229:11 amRNSDirector/PDMR Shareholding
9th Sep 20229:11 amRNSPublication of Base Prospectus
8th Sep 202212:58 pmRNSDirector/PDMR Shareholding
6th Sep 20221:00 pmRNSGSK provides update on FDA review of daprodustat
1st Sep 202211:48 amRNSTotal Voting Rights
24th Aug 20227:00 amRNSGSK Board changes
22nd Aug 20224:53 pmRNSDirector/PDMR Shareholding
17th Aug 20227:00 amRNSFDA New Drug Application File Acceptance for MMB
17th Aug 20227:00 amRNSStatement: Zantac (ranitidine) litigation update
16th Aug 20227:06 amRNSGSK completes acquisition of Affinivax, Inc.
12th Aug 20227:00 amRNSStatement: Zantac (ranitidine) litigation
11th Aug 202211:51 amRNSDirector/PDMR Shareholding
10th Aug 20224:57 pmRNSDirector/PDMR Shareholding
1st Aug 20226:10 pmRNSTotal Voting Rights
1st Aug 20221:43 pmRNSDirector/PDMR Shareholding
29th Jul 20222:00 pmRNSDirector/PDMR Shareholding
29th Jul 202210:00 amRNSGSK Board change
28th Jul 20221:01 pmRNSDirector/PDMR Shareholding
27th Jul 20227:00 amRNS2nd Quarter Results
26th Jul 20225:35 pmRNSHolding(s) in Company
22nd Jul 20224:45 pmRNSHolding(s) in Company
22nd Jul 20224:17 pmRNSBoard and Committee Changes
19th Jul 20227:00 amRNSCompletion of GSK Share Consolidation
18th Jul 20226:00 pmRNSHolding(s) in Company
18th Jul 20227:00 amRNSHaleon demerger completion and share consolidation
12th Jul 20229:48 amRNSDirector/PDMR Shareholding
11th Jul 20225:30 pmRNSGSK
8th Jul 20226:04 pmRNSDirector/PDMR Shareholding
8th Jul 20225:30 pmRNSDirector/PDMR Shareholding
8th Jul 20223:53 pmRNSDirector/PDMR Shareholding
8th Jul 20223:33 pmRNSDirector/PDMR Shareholding
8th Jul 20223:10 pmRNSDirector/PDMR Shareholding
6th Jul 20224:30 pmRNSResult of General Meeting
6th Jul 202210:11 amRNSDirector/PDMR Shareholding
5th Jul 202212:43 pmRNSGSK disclose discontinued operations from Q2 2022
5th Jul 20229:45 amRNSDirector/PDMR Shareholding
5th Jul 20229:30 amRNSDirector/PDMR Shareholding
1st Jul 20223:27 pmRNSTotal Voting Rights
1st Jul 20222:45 pmRNSGSK completes acquisition of Sierra Oncology
28th Jun 20225:56 pmRNSDirector/PDMR Shareholding
28th Jun 20227:00 amRNSGSK files Shingrix 18+ at risk indication in Japan
27th Jun 20224:08 pmRNSDirector/PDMR Shareholding
24th Jun 20223:44 pmRNSDirector/PDMR Shareholding
16th Jun 202210:58 amRNSDirector/PDMR Shareholding
10th Jun 20227:00 amRNSPositive phase III data for GSK’s RSV OA vaccine
9th Jun 20224:28 pmRNSDirector/PDMR Shareholding
7th Jun 20225:17 pmRNSDirector/PDMR Shareholding
7th Jun 202212:00 pmEQSHardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis
6th Jun 20227:00 amRNSUS FDA approval of Priorix

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.